Biofourmis announces its alliance with Novartis & Biofourmis acquired Biovotion AG

Southeast Asians were found to have a higher prevalence of coronary artery disease, hypertension and diabetes, all predisposing factors of heart failure, relative to their Northeast Asian counterparts, according to a study characterising regional and ethnic differences in heart failure across Asia.

Digital therapeutics company Biofourmis today announces its alliance with global healthcare company Novartis to deliver digital therapeutics for patients with heart failure. In this collaboration, Biofourmis and Novartis will be embarking on a project beginning with Southeast Asian countries to remotely manage heart failure patients to identify early signs of heart failure exacerbations in advance of a critical event. 

Instances of clinical exacerbation are predicted by Biofourmis’ clinically-proven and FDA-cleared Biovitals™ Analytics Engine, AI-powered health analytics ecosystem, allowing clinicians to deliver more personalised care and better patient outcomes.

Biofourmis has also acquired Switzerland-based Biovotion AG, a leading developer of a cutting-edge clinical-grade wearable biosensor platform. The acquisition includes leading wearable device Everion® along with more than 60 global patents. This will beef up Biofourmis’ Biovitals™ ecosystem, which is also utilised in the Novartis-Biofourmis partnership to monitor recently discharged heart failure patients and enable early intervention.

With this acquisition and alliance, Biofourmis expands to over 115 employees across Asia, the US and Europe. Founder and CEO Kuldeep Singh Rajput also anticipates reaching a $1 billion valuation for the company in the next 24 months.

Kuldeep Singh Rajput is from India though he did his Ph.D and founded Biofourmis in Singapore. He is an IIT Madras Alumni. Kuldeep was listed by Forbes as one of 30 Under 30 in Asia earlier this year and is an active member of the healthcare innovation and entrepreneurship community in Singapore. He is available for interactions and further coverage on the story.

Please let me know if you would like to speak with Kuldeep on the above news. The press releases have been attached for your easy reference and the press kit is available for download here.